Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: Specific implications for succinate dehydrogenase enzyme subunit B gene mutations

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 311-323

  Zelinka, Tomáš ^a,c   Timmers, Henri J L M ^a   Kozupa, Anna ^a   Chen, Clara C ^b   Carrasquillo, Jorge A ^b   Reynolds, James C ^b   Ling, Alexander ^b   Eisenhofer, Graeme ^b   Lazúrová, Ivica ^d   Adams, Karen T ^a   Whatley, Millie A ^b   Widimský Jr , Jiří ^c   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LONG BONE; LUMBAR SPINE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PELVIC GIRDLE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SACRUM; STATISTICAL SIGNIFICANCE; THORACIC SPINE;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; IRON-SULFUR PROTEINS; LIVER NEOPLASMS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIONUCLIDE IMAGING; RETROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 41349089524     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0217     Document Type: Article

References (41)

1. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A et al. 2005 Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology 23 8812-8818.
2. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R & Reiser HR 1988 Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of Internal Medicine 109 267-273.
3. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O et al. 2006 Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism 91 827-836.
4. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K 2006 High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 91 4505-4509.
5. Eisenhofer G, Goldstein DS, Stull R, Reiser HR, Sunderland T, Murphy DL & Kopin IJ 1986 Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clinical Chemistry 32 2030-2033.
6. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K & Langstrom B 2000 Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Quarterly Journal of Nuclear Medicine 44 68-76.
7. 131I-MIBG). Annals of the New York Academy of Sciences 1073 465-490.
8. Fogelman I, Cook G, Israel O & Van der Wall H 2005 Positron emission tomography and bone metastases. Seminars in Nuclear Medicine 35 135-142.
9. 123I-MIBG SPECT/CT. Journal of Nuclear Medicine 47 1635-1642.
10. 131I]- metaiodobenzylguanidine scintigraphy. International Journal of Urology 6 119-124.
11. Goldstein RE, O'Neill JA Jr, Holcomb GW III, Morgan WM III, Neblett WW III, Oates JA, Brown N, Nadeau J, Smith B, Page DL et al. 1999 Clinical experience over 48 years with pheochromocytoma. Annals of Surgery 229 755-764 (discussion 764-756).
12. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN & Ueno NT 2004 Bone imaging in metastatic breast cancer. Journal of Clinical Oncology 22 2942-2953.
13. van der Harst E, de Herder WW, Braining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP et al. 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 685-693.
14. 18F DOPA whole body PET - initial results. Radiology 222 507-512.
15. 131]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 88 4083-4087.
16. Ilias I, Shulkin B & Pacak K 2005 New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends in Endocrinology and Metabolism 16 66-72.
17. James RE, Baker HL Jr & Scanlon PW 1972 The roentgenologic aspects of metastatic pheochromocytoma. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 115 783-793.
18. John H, Ziegler WH, Hauri D & Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53 679-683.
19. Kimura N, Watanabe T, Noshiro T, Shizawa S & Miura Y 2005 Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocrine Pathology 16 23-32.
20. Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T & Isitman AT 1997 Diagnostic bone scanning in oncology. Seminars in Nuclear Medicine 27 107-141.
21. Lehnert H, Mundschenk J & Hahn K 2004 Malignant pheochromocytoma. Frontiers of Hormone Research 31 155-162.
22. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS & Kopin IJ 1993 Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clinical Chemistry 39 97-103.
23. Lenders JW, Eisenhofer G, Mannelli M & Pacak K 2005 Phaeochromocytoma. Lancet 366 665-675.
24. 131I-MIBG): a comprehensive review of 116 reported patients. Journal of Endocrinological Investigation 20 648-658.
25. Lynn MD, Braunstein EM, Wahl RL, Shapiro B, Gross MD & Rabbani R 1986 Bone metastases in pheochromocytoma: comparative studies of efficacy of imaging. Radiology 160 701-706.
26. 18F]-fluorodopamine- and [(123)I]-metaiodobenzyl-guanidine-negative metastatic pheochromocytoma sites. Nuclear Medicine Communications 27 31-36.
27. 18F] fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Annals of Surgical Oncology 13 187-197.
28. O'Riordain DS, Young WF Jr, Grant CS, Carney JA & van Heerden JA 1996 Clinical spectrum and outcome of functional extraadrenal paraganglioma. World Journal of Surgery 20 916-921.
29. Pacak K, Eisenhofer G & Goldstein DS 2004 Functional imaging of endocrine tumors: role of positron emission tomography. Endocrine Reviews 25 568-580.
30. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM & Tischler AS 2007 Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nature Clinical Practice. Endocrinology and Metabolism 3 92-102.
31. Plouin PF, Chatellier G, Fofol I & Corvol P 1997 Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29 1133-1139.
32. Roodman GD 2004 Mechanisms of bone metastasis. New England Journal of Medicine 350 1655-1664.
33. Rufini V, Calcagni ML & Baum RP 2006 Imaging of neuroendocrine tumors. Seminars in Nuclear Medicine 36 228-247.
34. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP et al. 1992 Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. Journal of Endocrinological Investigation 15 631-642.
35. Shulkin BL, Thompson NW, Shapiro B, Francis IR & Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212 35-41.
36. Sundin A, Garske U & Orlefors H 2007 Nuclear imaging of neuroendocrine tumours. Best Practice and Research. Clinical Endocrinology and Metabolism 21 69-85.
37. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW & Pacak K 2007 Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism 92 779-786.
38. 11C hydroxyephedrine PET. Radiology 230 423-428.
39. Vassilopoulou-Sellin R 1998 Clinical outcome of 50 patients with malignant abdominal paragangliomas and malignant pheochromocytomas. Endocrine-Related Cancer 5 59-68.
40. Yu J & Pacak K 2002 Management of malignant pheochromocytoma. Endocrinologist 12 291-299.
41. Zarnegar R, Kebebew E, Duh QY & Clark OH 2006 Malignant pheochromocytoma. Surgical Oncology Clinics of North America 15 555-571.